Piscataway, NJ1 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Piscataway, NJ

Find 1 actively recruiting myalgic encephalomyelitis clinical trials in Piscataway, NJ. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
140
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Piscataway

About Myalgic Encephalomyelitis Clinical Trials in Piscataway

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 1 myalgic encephalomyelitis clinical trials recruiting participants in Piscataway, NJ. These studies are seeking a combined 140 participants. Research is being sponsored by Johns Hopkins University. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Piscataway — FAQ

Are there myalgic encephalomyelitis clinical trials in Piscataway?

Yes, there are 1 myalgic encephalomyelitis clinical trials currently recruiting in Piscataway, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Piscataway?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Piscataway research site will contact you about next steps.

Are clinical trials in Piscataway free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Piscataway studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 1 active trials in Piscataway are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated July 19, 2026 from ClinicalTrials.gov